Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00445484
What this trial is testing

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 22
Testing effectiveness (Phase 2)Study completedNCT02119468
What this trial is testing

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell MyelomaRecurrent Plasma Cell Myeloma
City of Hope Medical Center 32
Testing effectiveness (Phase 2)Ended earlyNCT03683277
What this trial is testing

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

Who this might be right for
Multiple MyelomaRelapsed and Refractory Multiple MyelomaGenetic Condition
Intergroupe Francophone du Myelome 26
Not applicableNo Longer AvailableNCT05462639
What this trial is testing

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer
Early research (Phase 1)Ended earlyNCT06304636
What this trial is testing

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Cartesian Therapeutics 4
Early research (Phase 1)Looking for participantsNCT07333430
What this trial is testing

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (MM)
Hadassah Medical Organization 60
Large-scale testing (Phase 3)UnknownNCT00747877
What this trial is testing

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Leeds Cancer Centre at St. James's University Hospital 460
Testing effectiveness (Phase 2)Study completedNCT00051311
What this trial is testing

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Who this might be right for
Hematologic Neoplasms
National Cancer Institute (NCI) 62
Testing effectiveness (Phase 2)Study completedNCT01083602
What this trial is testing

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Who this might be right for
Relapsed and Bortezomib Refractory Multiple MyelomaRefractory Multiple MyelomaMultiple Myeloma in Relapse
Novartis Pharmaceuticals 55
Early research (Phase 1)Study completedNCT01301807
What this trial is testing

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Non-Secretory Plasma Cell MyelomaPlasmacytosisRecurrent Plasma Cell Myeloma+1 more
M.D. Anderson Cancer Center 63
Testing effectiveness (Phase 2)Study completedNCT00639002
What this trial is testing

Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Incyte Corporation 13
Early research (Phase 1)Ended earlyNCT00004239
What this trial is testing

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+2 more
Alliance for Clinical Trials in Oncology 10
Large-scale testing (Phase 3)Study completedNCT00048230
What this trial is testing

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 620
Large-scale testing (Phase 3)Study completedNCT03275285
What this trial is testing

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 302
Testing effectiveness (Phase 2)Study completedNCT01145989
What this trial is testing

AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
NCIC Clinical Trials Group 8
Testing effectiveness (Phase 2)Study completedNCT00078858
What this trial is testing

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+132 more
Fred Hutchinson Cancer Center 37
Testing effectiveness (Phase 2)Ended earlyNCT02863991
What this trial is testing

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Jazz Pharmaceuticals 17
Testing effectiveness (Phase 2)Ended earlyNCT00792506
What this trial is testing

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Italfarmaco 1
Testing effectiveness (Phase 2)Study completedNCT01866293
What this trial is testing

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center 11
Testing effectiveness (Phase 2)UnknownNCT03140943
What this trial is testing

Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
National University Hospital, Singapore 100
Next Page